Vice President, Neuroscience Arvinas IncVice President, NeuroscienceNew Haven, CTThis differentiated approach has enabled Arvinas to build a broad pipeline of investigational therapies across oncology and neurodegenerative diseases, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal bulbar muscular atrophy; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Establishes and leads strategic collaborations with biopharma partners, key scientific investigators, contract research organizations, academic institutions, and external partners to advance translational neuroscience, induced pluripotent stem cell models, biomarker assay capabilities, including assay transfer, method development, qualification, validation, and clinical implementation.